Jump to content

Duvelisib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
update links
Monkbot (talk | contribs)
Bots
3,695,952 edits
m Task 17: replace to-be-deprecated: |name-list-format= (3× replaced; usage: 3 of 3);
Line 75: Line 75:


==History==
==History==
Duvelisib, also known as IPI-145, was discovered by Intellikine,<ref>{{cite web|title=Duvelisib|url=http://adisinsight.springer.com/drugs/800035173|publisher=AdisInsight|access-date=11 January 2017}}</ref> a company founded in September 2007 based on biochemistry research from the lab of [[Kevan Shokat]] at the [[University of California, San Francisco|University of California San Francisco]].<ref name=XconomyTakeda>{{cite news|last1=Timmerman|first1=Luke | name-list-format = vanc |title=Millennium: Takeda Acquires San Diego's Intellikine for $190M Upfront|url=http://www.xconomy.com/boston/2011/12/20/millennium-takeda-acquires-san-diegos-intellikine-for-190m-upfront/|work=Xconomy|date=20 December 2011}}</ref>
Duvelisib, also known as IPI-145, was discovered by Intellikine,<ref>{{cite web|title=Duvelisib|url=http://adisinsight.springer.com/drugs/800035173|publisher=AdisInsight|access-date=11 January 2017}}</ref> a company founded in September 2007 based on biochemistry research from the lab of [[Kevan Shokat]] at the [[University of California, San Francisco|University of California San Francisco]].<ref name=XconomyTakeda>{{cite news|last1=Timmerman|first1=Luke | name-list-style = vanc |title=Millennium: Takeda Acquires San Diego's Intellikine for $190M Upfront|url=http://www.xconomy.com/boston/2011/12/20/millennium-takeda-acquires-san-diegos-intellikine-for-190m-upfront/|work=Xconomy|date=20 December 2011}}</ref>


In mid-June 2016, Infinity announced results of Phase II clinical trial of duvelisib.<ref name=Anastasia2016rev>{{cite journal | vauthors = Anastasia A, Rossi G | title = Novel Drugs in Follicular Lymphoma | journal = Mediterranean Journal of Hematology and Infectious Diseases | volume = 8 | issue = 1 | pages = e2016061 | date = 1 November 2016 | pmid = 27872741 | pmc = 5111511 | doi = 10.4084/MJHID.2016.061 }}</ref>
In mid-June 2016, Infinity announced results of Phase II clinical trial of duvelisib.<ref name=Anastasia2016rev>{{cite journal | vauthors = Anastasia A, Rossi G | title = Novel Drugs in Follicular Lymphoma | journal = Mediterranean Journal of Hematology and Infectious Diseases | volume = 8 | issue = 1 | pages = e2016061 | date = 1 November 2016 | pmid = 27872741 | pmc = 5111511 | doi = 10.4084/MJHID.2016.061 }}</ref>


In November 2016, Infinity exclusively licensed the worldwide rights to duvelisib to Verastem Oncology for little money compared to earlier deals; the deal included no upfront payment, a $6 million milestone for success in a Phase 3 trial in chronic lymphocytic leukemia, a $22 million payment for an FDA approval, and royalties.<ref name=XconomyVerastem>{{cite news|last1=Fidler|first1=Ben| name-list-format = vanc |title=Verastem Takes a Low-Cost Flier on Infinity's Blood Cancer Drug|url=http://www.xconomy.com/boston/2016/11/02/verastem-takes-a-low-cost-flier-on-infinitys-blood-cancer-drug/|work=Xconomy|date=2 November 2016}}</ref>
In November 2016, Infinity exclusively licensed the worldwide rights to duvelisib to Verastem Oncology for little money compared to earlier deals; the deal included no upfront payment, a $6 million milestone for success in a Phase 3 trial in chronic lymphocytic leukemia, a $22 million payment for an FDA approval, and royalties.<ref name=XconomyVerastem>{{cite news|last1=Fidler|first1=Ben| name-list-style = vanc |title=Verastem Takes a Low-Cost Flier on Infinity's Blood Cancer Drug|url=http://www.xconomy.com/boston/2016/11/02/verastem-takes-a-low-cost-flier-on-infinitys-blood-cancer-drug/|work=Xconomy|date=2 November 2016}}</ref>


Duvelisib has received [[orphan drug]] designation in the United States for treatment of peripheral [[T-cell_lymphoma|T-cell lymphoma]] (PTCL) in 2019.<ref>{{cite web|title=Copiktra Receives FDA's Orphan Drug Status for T-cell Lymphoma Treatment|url=https://lymphomanewstoday.com/2019/10/10/copiktra-receives-fda-orphan-drug-designation-for-t-cell-lymphoma/|publisher=Lymphoma News Today|access-date=5 November 2019}}</ref>
Duvelisib has received [[orphan drug]] designation in the United States for treatment of peripheral [[T-cell_lymphoma|T-cell lymphoma]] (PTCL) in 2019.<ref>{{cite web|title=Copiktra Receives FDA's Orphan Drug Status for T-cell Lymphoma Treatment|url=https://lymphomanewstoday.com/2019/10/10/copiktra-receives-fda-orphan-drug-designation-for-t-cell-lymphoma/|publisher=Lymphoma News Today|access-date=5 November 2019}}</ref>
Line 88: Line 88:
In April 2018, Verastem filed a New Drug Application (NDA) for duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed or refractory follicular lymphoma (FL). The FDA approved the application in September 2018.<ref>{{cite news|title=Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm|work=FDA|date=24 September 2018}}</ref><ref>{{Cite news|url=https://www.businesswire.com/news/home/20180409005377/en/FDA-Accepts-New-Drug-Application-Duvelisib-Grants|title=FDA Accepts New Drug Application for Duvelisib and Grants Priority Review |date=2018-07-07}}</ref>
In April 2018, Verastem filed a New Drug Application (NDA) for duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed or refractory follicular lymphoma (FL). The FDA approved the application in September 2018.<ref>{{cite news|title=Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm|work=FDA|date=24 September 2018}}</ref><ref>{{Cite news|url=https://www.businesswire.com/news/home/20180409005377/en/FDA-Accepts-New-Drug-Application-Duvelisib-Grants|title=FDA Accepts New Drug Application for Duvelisib and Grants Priority Review |date=2018-07-07}}</ref>


Duvelisib is intended to be used in patients who have received at least two prior systemic therapies, and carries a [[black box warning]] due to the risk of fatal/serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.<ref>{{cite news|last1=Carroll|first1=John| name-list-format = vanc |title=Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success |url=https://endpts.com/unwanted-by-abbvie-and-infinity-verastem-gets-an-ok-for-duvelisib-and-a-second-shot-at-success/ |work=Endpoints News|date=24 September 2018}}</ref>
Duvelisib is intended to be used in patients who have received at least two prior systemic therapies, and carries a [[black box warning]] due to the risk of fatal/serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.<ref>{{cite news|last1=Carroll|first1=John| name-list-style = vanc |title=Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success |url=https://endpts.com/unwanted-by-abbvie-and-infinity-verastem-gets-an-ok-for-duvelisib-and-a-second-shot-at-success/ |work=Endpoints News|date=24 September 2018}}</ref>


== See also ==
== See also ==

Revision as of 17:40, 19 October 2020

Duvelisib
Clinical data
Pronunciationdoo-VE-li-SIB
Trade namesCopiktra
AHFS/Drugs.comMonograph
MedlinePlusa618056
License data
Routes of
administration		By mouth (capsules)
Drug classPI3-Kinase inhibitor
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Metabolismmainly metabolized by CYP3A4[2]
Onset of action1-2 hours after initial administration
Elimination half-life5.2 to 10.9 hours
ExcretionFeces (79%), urine (14%)
Identifiers
  • 8-Chloro-2-phenyl-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.245.560 Edit this at Wikidata
Chemical and physical data
FormulaC22H17ClN6O
Molar mass416.87 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after other treatments have failed.[3] It is taken by mouth.[3]

Common side effects include diarrhea, low white blood cells, rash, feeling tired, fever, and muscle pains.[3] Other serious side effects include inflammation of the lungs and infections.[3] It is a dual inhibitor of PI3Kδ and PI3Kγ.[4] Duvelisib is manufactured by Verastem Oncology.

Medical uses

It is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed.[3] Further trials are ongoing to confirm benefits as of 2019.[3]

Mechanism of action

Duvelisib is a Phosphoinositide 3-kinase inhibitor, specifically of the delta and gamma isoforms of PI3K.[5] This class of compounds works by preventing PI3K from playing its role in transducing signals from outside of cells into various intracellular pathways involved in cell cycle regulation, apoptosis, DNA repair, senescence, angiogenesis and cell metabolism, including the PI3K/AKT/mTOR pathway.[5]

History

Duvelisib, also known as IPI-145, was discovered by Intellikine,[6] a company founded in September 2007 based on biochemistry research from the lab of Kevan Shokat at the University of California San Francisco.[7]

In mid-June 2016, Infinity announced results of Phase II clinical trial of duvelisib.[5]

In November 2016, Infinity exclusively licensed the worldwide rights to duvelisib to Verastem Oncology for little money compared to earlier deals; the deal included no upfront payment, a $6 million milestone for success in a Phase 3 trial in chronic lymphocytic leukemia, a $22 million payment for an FDA approval, and royalties.[8]

Duvelisib has received orphan drug designation in the United States for treatment of peripheral T-cell lymphoma (PTCL) in 2019.[9]

Society and culture

In April 2018, Verastem filed a New Drug Application (NDA) for duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed or refractory follicular lymphoma (FL). The FDA approved the application in September 2018.[10][11]

Duvelisib is intended to be used in patients who have received at least two prior systemic therapies, and carries a black box warning due to the risk of fatal/serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.[12]

See also

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ "Full prescribing information: COPIKTRA (duvelisib)" (PDF). U.S. Food and Drug Administration. Retrieved 23 October 2018.
  3. ^ a b c d e f "Duvelisib Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 28 February 2019.
  4. ^ "duvelisib (Rx)". Medscape. Retrieved 24 September 2018.
  5. ^ a b c Anastasia A, Rossi G (1 November 2016). "Novel Drugs in Follicular Lymphoma". Mediterranean Journal of Hematology and Infectious Diseases. 8 (1): e2016061. doi:10.4084/MJHID.2016.061. PMC 5111511. PMID 27872741.
  6. ^ "Duvelisib". AdisInsight. Retrieved 11 January 2017.
  7. ^ Timmerman L (20 December 2011). "Millennium: Takeda Acquires San Diego's Intellikine for $190M Upfront". Xconomy.
  8. ^ Fidler B (2 November 2016). "Verastem Takes a Low-Cost Flier on Infinity's Blood Cancer Drug". Xconomy.
  9. ^ "Copiktra Receives FDA's Orphan Drug Status for T-cell Lymphoma Treatment". Lymphoma News Today. Retrieved 5 November 2019.
  10. ^ "Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)". FDA. 24 September 2018.
  11. ^ "FDA Accepts New Drug Application for Duvelisib and Grants Priority Review". 2018-07-07.
  12. ^ Carroll J (24 September 2018). "Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success". Endpoints News.
  • "Duvelisib". Drug Information Portal. U.S. National Library of Medicine.
  • "Duvelisib". National Cancer Institute.
  • "Duvelisib". NCI Drug Dictionary. National Cancer Institute.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Duvelisib&oldid=984353191"